We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
M&A surge, capital revival lift biotech ETFs like IBB, XBI, CANC & IDNA.
Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF (IBB - Free Report) rallied 36.7% in six months ending Jan. 7, 2026, outperforming SPDR S&P 500 ETF Trust (SPY - Free Report) (up 11.2%). Year to date, IBB has risen 4.2% compared with SPY’s 0.6% gain.
Note that IBB has surged 31.1% over the past one year (as of Jan. 7, 2026). The performance marked a sharp turnaround in 2025. The MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index (USD) offered muted returns of 3.74% in 2024 and 0.97% in 2023. The returns were too shallow, given the 25.1% and 27.1% returns offered by the MSCI USA index, respectively, in 2024 and 2023.
More specifically, the Biomedical and Genetics industry has returned 11.7% over the past three-month period, respectively, outstripping returns offered by the S&P 500 (up 3.3%) (at the time of writing).
Reasons Behind the Rally
The space has surged lately due to a host of factors. Below, we highlight a few of them.
The PEG ratio of the Biomedical and Genetics industry was 1.54X versus the 2.06X ratio held by the S&P 500. Moreover, projected EPS growth for the Biomedical and Genetics stocks is 12.14% versus the S&P 500’s 9.15%.
Fed Rate Cut
Biotech companies usually remain in need of cheaper funding. The Fed enacted three rate cuts in 2025. The central bank may cut rates further in the coming days. Biotech, being a high-growth sector, performs well in a lower rate environment.
Clinical & Regulatory Wins
In 2025, the FDA approved quite a few biotechnology drugs, including dordaviprone for diffuse midline glioma, sunvozertinib for non-small cell lung cancer and linvoseltamab-gcpt for multiple myeloma.
Other approvals include Wayrilz (rilzabrutinib) for immune thrombocytopenia and paltusotine for acromegaly. About 46 approvals were recorded in 2025, followed by 50 approvals in 2024 and about 55 approvals in 2023. Positive drug-trial results now reward stocks. The momentum is carrying into 2026 with launches like the first oral GLP-1 obesity pill, energizing the space.???
Regulatory Tailwinds in the Cards?
Lingering uncertainties around tariffs and trade measures are concerning. Then again, Pfizer recently struck a deal with the U.S. government to lower prices on certain drugs for Americans enrolled in Medicaid, and committed to investing $70 billion in the United States. In return, the company secured a three-year reprieve from import tariffs. AstraZeneca, too, made a deal with Trump to lower drug prices and dodge tariffs (read: 4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio).
M&A & Capital Revival
Deal volume hit decade highs in 2025 (nearly 70 deals), driven by Big Pharma's patent cliff needs, boosting sentiment into 2026. Per UBS, follow-on offerings reached $10 billion in fourth-quarter 2025 — the strongest in nearly two years, reopening IPO windows, as quoted on Investing.
Biopharma venture investment totaled $5.8 billion across 86 rounds in the third quarter of 2025, per a J.P. Morgan report issued on Oct. 15, 2025, taking the year-to-date number to $17.1 billion.
The J.P. Morgan report went on to highlight that the licensing scenario continued to support larger, later-stage deals in the third quarter of 2025, with biopharma licensing reaching $63.7 billion in quarterly announced value and $183.7 billion in the year-to-date frame.
Biotech ETFs in Focus
The following biotech ETFs have been hovering around a one-year high. These ETFs include Tema Oncology ETF (CANC - Free Report) , S&P Biotech SPDR (XBI - Free Report) , Genomics Immunology and Health ETF (IDNA - Free Report) and IBB.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Biotech ETFs Are Rallying Hard
Key Takeaways
Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF (IBB - Free Report) rallied 36.7% in six months ending Jan. 7, 2026, outperforming SPDR S&P 500 ETF Trust (SPY - Free Report) (up 11.2%). Year to date, IBB has risen 4.2% compared with SPY’s 0.6% gain.
Note that IBB has surged 31.1% over the past one year (as of Jan. 7, 2026). The performance marked a sharp turnaround in 2025. The MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index (USD) offered muted returns of 3.74% in 2024 and 0.97% in 2023. The returns were too shallow, given the 25.1% and 27.1% returns offered by the MSCI USA index, respectively, in 2024 and 2023.
More specifically, the Biomedical and Genetics industry has returned 11.7% over the past three-month period, respectively, outstripping returns offered by the S&P 500 (up 3.3%) (at the time of writing).
Reasons Behind the Rally
The space has surged lately due to a host of factors. Below, we highlight a few of them.
Decent Valuations of Biotech
Even with the recent rally, biotech stocks trade below the broader stock market. The MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index traded at a forward P/E of 24.36X versus 27.81X possessed by the MSCI USA index as of Dec. 31, 2025.
The PEG ratio of the Biomedical and Genetics industry was 1.54X versus the 2.06X ratio held by the S&P 500. Moreover, projected EPS growth for the Biomedical and Genetics stocks is 12.14% versus the S&P 500’s 9.15%.
Fed Rate Cut
Biotech companies usually remain in need of cheaper funding. The Fed enacted three rate cuts in 2025. The central bank may cut rates further in the coming days. Biotech, being a high-growth sector, performs well in a lower rate environment.
Clinical & Regulatory Wins
In 2025, the FDA approved quite a few biotechnology drugs, including dordaviprone for diffuse midline glioma, sunvozertinib for non-small cell lung cancer and linvoseltamab-gcpt for multiple myeloma.
Other approvals include Wayrilz (rilzabrutinib) for immune thrombocytopenia and paltusotine for acromegaly. About 46 approvals were recorded in 2025, followed by 50 approvals in 2024 and about 55 approvals in 2023. Positive drug-trial results now reward stocks. The momentum is carrying into 2026 with launches like the first oral GLP-1 obesity pill, energizing the space.???
Regulatory Tailwinds in the Cards?
Lingering uncertainties around tariffs and trade measures are concerning. Then again, Pfizer recently struck a deal with the U.S. government to lower prices on certain drugs for Americans enrolled in Medicaid, and committed to investing $70 billion in the United States. In return, the company secured a three-year reprieve from import tariffs. AstraZeneca, too, made a deal with Trump to lower drug prices and dodge tariffs (read: 4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio).
M&A & Capital Revival
Deal volume hit decade highs in 2025 (nearly 70 deals), driven by Big Pharma's patent cliff needs, boosting sentiment into 2026. Per UBS, follow-on offerings reached $10 billion in fourth-quarter 2025 — the strongest in nearly two years, reopening IPO windows, as quoted on Investing.
Biopharma venture investment totaled $5.8 billion across 86 rounds in the third quarter of 2025, per a J.P. Morgan report issued on Oct. 15, 2025, taking the year-to-date number to $17.1 billion.
The J.P. Morgan report went on to highlight that the licensing scenario continued to support larger, later-stage deals in the third quarter of 2025, with biopharma licensing reaching $63.7 billion in quarterly announced value and $183.7 billion in the year-to-date frame.
Biotech ETFs in Focus
The following biotech ETFs have been hovering around a one-year high. These ETFs include Tema Oncology ETF (CANC - Free Report) , S&P Biotech SPDR (XBI - Free Report) , Genomics Immunology and Health ETF (IDNA - Free Report) and IBB.